The east wind of the biopharmaceutical industry has arrived, and the performance of upstream pharmaceutical equipment is expected to continue to increase

2021 is the final decade of "Healthy China 2030" entering a new journey, and also the beginning of the "14th Five-Year Plan"
.
This year, China's biomedical industry has been promoted to an important height as a pillar industry.
Driven by a series of favorable policies and measures, it has ushered in a blowout and innovative development
.
The industry believes that the east wind of the biopharmaceutical industry has arrived, and the performance of upstream pharmaceutical equipment is expected to continue to increase under the trend of domestic substitution and overseas exports
.
Pharmaceutical equipment (picture source: Pharmaceutical Network) The biopharmaceutical industry has already started late in the biopharmaceutical industry in China, but after more than ten years of development, Chinese pharmaceutical companies have become a new force in the global biomedicine field.
In recent years, they have been in genetic engineering drugs.
The continuous development of biopharmaceutical fields such as, antibody drugs, cell drugs, etc.
, has led to the continuous expansion of the entire industry, and the market prospects are broad
.
Since 2021, the importance of the development of the biopharmaceutical industry has once again been raised to a high level.
Favorable policies at the national and local levels have been continuously promulgated to support the development and growth of China's biopharmaceutical industry and its internationalization and intensive high-quality development
.
For example, according to the "14th Five-Year Plan and 2035 Vision Goals Outline", China will focus on strengthening strategic scientific and technological strength, focusing on major innovation fields such as biomedicine, establishing a number of national laboratories, reorganizing state key laboratories, and forming a rational structure and operation.
Efficient laboratory system
.
Optimize and upgrade innovation bases such as the National Engineering Research Center and the National Technology Innovation Center
.
Increase public relations in the frontier fields of science and technology, including genetics and biotechnology; for example, in the "14th Five-Year Plan for the Development of Biomedicine Industry", the strategic emerging industry status of the biomedical industry was again emphasized, and the development of biomedicine and other industries was clearly accelerated.
Make the bio-economy bigger and stronger
.
It can be said that China has regarded biomedicine as an emerging strategic industry that is "emerging the power of the whole country", and the promulgation of these heavy policies will benefit the biomedical industry for a long time
.
Data show that the market size of China's biopharmaceutical industry has reached 350 billion yuan in 2019, and it is approaching the 400 billion yuan mark in 2020
.
According to the Frost & Sullivan report, my country’s biopharmaceutical market will exceed US$100 billion by 2024..
The performance of domestic pharmaceutical equipment is expected to continue to increase.
In the context of the vigorous development of biopharmaceutical technology, the demand for upstream pharmaceutical equipment is expected to be continuously driven.
At the same time, with the popularization of intelligent manufacturing, artificial intelligence, and Industry 4.
0, the pharmaceutical industry is accelerating its transformation and upgrading.
The market demand for high-end pharmaceutical equipment will also grow further
.
In the medium and long term, the performance of domestic pharmaceutical equipment is expected to continue to increase
.
On the one hand, the pace of import substitution of domestic pharmaceutical equipment has accelerated
.
Especially since 2020, under the background of delayed delivery of imported equipment, domestic pharmaceutical equipment with good quality and high cost performance has been further favored by local pharmaceutical companies, and it is expected to continue to replace imports by strengthening R&D and innovation; on the other hand, domestically produced pharmaceutical equipment Pharmaceutical equipment is also speeding up to go overseas.
In 2021, many domestically-made equipment have won the attention and support of overseas customers at various large-scale pharmaceutical machinery exhibitions.
It can be seen that the strength of domestic pharmaceutical equipment has improved.
Accelerating the international layout will also become a growth point for many companies
.
Guosheng Securities recently released a report stating that it is optimistic about the high-prosperity manufacturing in China under import substitution: upstream biopharmaceutical equipment (Teflon, Chutian Technology, Tailin Biology, etc.
)
.
At present, Chutian Technology has been the first to disclose the report for the third quarter of 2021.
In the first three quarters, it created operating income of 3.
682 billion yuan, an increase of 67.
24% year-on-year, and realized a net profit of 401 million yuan, an increase of 723.
53% year-on-year
.
The reason for the increase in performance was that new orders increased by 98% compared with the same period last year.
The company increased production, delivery and debugging efforts, which resulted in a substantial increase in revenue and operating costs compared with the same period last year
.
It is worth mentioning that in the first three quarters, Chutian Technology’s revenue and orders from the biopharmaceutical equipment sector accounted for about 40% of the company’s share, which is enough to show that the demand for biopharmaceutical equipment is strong
.
In the face of the vast blue ocean of the market, in order to seize the opportunity, pharmaceutical companies such as Chutian Technology and Dongfulong are actively deploying in the field of biopharmaceuticals
.
For example, Chutian Technology recently announced the establishment of a subsidiary, Microsphere Biology, to enter the field of microspheres and filler media. .
Regarding this action, the company stated that entering the field of microspheres and filler media is an inevitable move of Chutian Technology's "One Vertical, One Horizontal, One Platform" and "2030" strategy, and it is also an important node for conquering key biopharmaceutical technologies; October 14 On the day, Tofflon invested nearly 500 million yuan in the construction of a pharmaceutical system equipment production base to sign a contract with Shanghai Jinshan Industrial Zone.
It is reported that the project will build a high-end, intelligent, and digital advanced manufacturing platform, and use professional technology to serve the biomedical industry.
Development
.